Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk's Wegovy demonstrated a significant 57% greater reduction in major adverse cardiovascular events (MACE) compared to Eli Lilly's tirzepatide in a real-world study of obese/overweight patients with established cardiovascular disease. This superior cardiovascular benefit, alongside Novo Nordisk's intention to seek U.S. regulatory approval for a high-dose Wegovy to match Zepbound's weight-loss efficacy, strengthens Wegovy's competitive positioning in the GLP-1 market and drove NVO stock up 7.63% premarket.

Analysis

Novo Nordisk has presented compelling real-world evidence from its STEER study, significantly strengthening the competitive profile of Wegovy (semaglutide) against Eli Lilly’s tirzepatide. The study, involving patients with overweight or obesity and established cardiovascular disease (CVD), showed that Wegovy delivered a 57% greater risk reduction for major adverse cardiovascular events (MACE) compared to tirzepatide among patients with consistent treatment adherence. The absolute event rates were notably lower for Wegovy at 0.1% versus 0.4% for tirzepatide. Even in a broader cohort including patients with treatment gaps, Wegovy maintained a significant 29% risk reduction advantage for heart attack, stroke, and all-cause death. This data provides a crucial differentiator in the highly competitive obesity drug market, positioning Wegovy not just as a weight-loss treatment but as a superior option for cardiovascular risk mitigation in this specific high-risk population. This clinical advantage is compounded by Novo Nordisk's strategic plan to seek U.S. regulatory approval for a high-dose Wegovy, a move aimed at matching the weight-loss efficacy of Lilly's Zepbound. The market's immediate validation, reflected in a 7.63% premarket surge in NVO stock, underscores the financial significance of these developments.

Key Decisions for Investors

• The positive STEER study data significantly strengthens the bull case for Novo Nordisk, suggesting investors should re-evaluate Wegovy's long-term market share potential against Eli Lilly's tirzepatide, particularly in patient populations with cardiovascular comorbidities.
• Investors holding Eli Lilly should monitor for potential headwinds in prescription trends and payer negotiations for tirzepatide, as this real-world evidence places the drug at a competitive disadvantage for patients with established cardiovascular disease.
• The next key catalyst to watch is Novo Nordisk's planned U.S. regulatory submission for a high-dose Wegovy, as approval would directly challenge Zepbound's primary advantage in weight-loss efficacy and could further shift the competitive balance in the obesity market.